Hanako Kikuchi Selected Research

Pulmonary Arterial Hypertension

11/2023	Transition from Intravenous Epoprostenol to Treprostinil Due to Intolerable Side Effects in Patients With Pulmonary Arterial Hypertension.
9/2022	Reversible Cardiac Hypertrophy in Pulmonary Arterial Hypertension Treated With High-Dose Epoprostenol.
1/2022	Successful epoprostenol withdrawal and termination with an aid of the exercise stress test in pulmonary arterial hypertension.
3/2020	Pulmonary Artery Pressure as a Treatment Target to Improve the Prognosis of Idiopathic Pulmonary Arterial Hypertension　- Insight From a Cohort From Two Japanese Pulmonary Hypertension Centers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hanako Kikuchi Research Topics

Disease

6	Pulmonary Hypertension 04/2024 - 01/2021
4	Pulmonary Arterial Hypertension 11/2023 - 03/2020
1	Thrombocytopenia (Thrombopenia) 11/2023
1	High Cardiac Output 11/2023
1	Ascites 11/2023
1	Connective Tissue Diseases (Connective Tissue Disease) 11/2023
1	Heart Diseases (Heart Disease) 01/2023
1	Polycythemia Vera 01/2023
1	Hypertrophy 09/2022
1	Cardiomegaly (Heart Hypertrophy) 09/2022
1	Dyspnea (Shortness of Breath) 09/2022
1	Familial Primary Pulmonary Hypertension 09/2022
1	Sleep Apnea Syndromes (Sleep Apnea) 11/2018

Drug/Important Bio-Agent (IBA)

4	Epoprostenol (Prostacyclin)FDA LinkGeneric 11/2023 - 03/2020
2	treprostinil FDA Link 11/2023 - 09/2022
2	Oxygen (Dioxygen)IBA 01/2022 - 11/2018
1	cytidylyl-(3'-5')-cytidine (CpC)IBA 01/2023
1	Clostridium perfringens epsilon-toxinIBA 01/2023
1	ProstaglandinsIBA 09/2022

Therapy/Procedure

3	Therapeutics 01/2023 - 01/2021
1	Aftercare (After-Treatment) 04/2024